Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands; Department of Biomedical Genetics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht University, 3584 EA Utrecht, the Netherlands; German Cancer Consortium (DKTK) standort Freiburg and German Cancer Research Center (DKFZ), 79106 Heidelberg, Germany.
Regenerative Medicine Center and Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, 3584 CT Utrecht, the Netherlands; German Cancer Consortium (DKTK) standort Freiburg and German Cancer Research Center (DKFZ), 79106 Heidelberg, Germany.
Am J Hum Genet. 2019 Aug 1;105(2):283-301. doi: 10.1016/j.ajhg.2019.06.016. Epub 2019 Jul 25.
The RNA polymerase II complex (pol II) is responsible for transcription of all ∼21,000 human protein-encoding genes. Here, we describe sixteen individuals harboring de novo heterozygous variants in POLR2A, encoding RPB1, the largest subunit of pol II. An iterative approach combining structural evaluation and mass spectrometry analyses, the use of S. cerevisiae as a model system, and the assessment of cell viability in HeLa cells allowed us to classify eleven variants as probably disease-causing and four variants as possibly disease-causing. The significance of one variant remains unresolved. By quantification of phenotypic severity, we could distinguish mild and severe phenotypic consequences of the disease-causing variants. Missense variants expected to exert only mild structural effects led to a malfunctioning pol II enzyme, thereby inducing a dominant-negative effect on gene transcription. Intriguingly, individuals carrying these variants presented with a severe phenotype dominated by profound infantile-onset hypotonia and developmental delay. Conversely, individuals carrying variants expected to result in complete loss of function, thus reduced levels of functional pol II from the normal allele, exhibited the mildest phenotypes. We conclude that subtle variants that are central in functionally important domains of POLR2A cause a neurodevelopmental syndrome characterized by profound infantile-onset hypotonia and developmental delay through a dominant-negative effect on pol-II-mediated transcription of DNA.
RNA 聚合酶 II 复合物(pol II)负责转录所有约 21000 个人类蛋白编码基因。在这里,我们描述了 16 名个体携带新的杂合变异体在 POLR2A 中,编码 RPB1,是 pol II 的最大亚基。我们采用结合结构评估和质谱分析的迭代方法、使用酿酒酵母作为模型系统,并评估 HeLa 细胞的细胞活力,将 11 个变体归类为可能致病的,4 个变体可能致病。一个变体的意义仍未解决。通过表型严重程度的定量,我们可以区分致病变体的轻度和重度表型后果。预计仅产生轻微结构影响的错义变体导致 pol II 酶功能失调,从而对基因转录产生显性负效应。有趣的是,携带这些变体的个体表现出严重的表型,主要表现为严重的婴儿期起病的张力减退和发育迟缓。相反,携带预计导致完全丧失功能的变体的个体,因此从正常等位基因减少功能性 pol II 的水平,表现出最轻微的表型。我们得出结论,功能上重要的 POLR2A 区域的细微变异体通过对 pol-II 介导的 DNA 转录的显性负效应导致神经发育综合征,其特征是严重的婴儿期起病的张力减退和发育迟缓。